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and how the vaccine relates to sexual activity were the
most signiﬁcant predictors of vaccine uptake. Future public
health HPV vaccine campaigns must address these issues.
doi:10.1016/j.ijid.2010.02.623452 14
ate prime-boosting strategies, and the cost-effectiveness
f mass-vaccination programmes.
oi:10.1016/j.ijid.2010.02.621
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Background: Dengue is an important re-emerging disease
ffecting humans in more than 100 countries worldwide.
resently, over 2.5 billion people live in risk areas and 50
o 100 million people suffer from dengue fever (DF) each
ear. The World health Organization (WHO) estimates that
urrently 500,000 cases of Dengue Hemorrahagic Fever /
engue Shock Syndrome (DHF/DSS) and more than 20,000
eaths occur per year. At the moment, there are no
ffective vaccines or drugs available to prevent or treat
engue disease. Chimeric viruses, DNA, inactivated and sub-
nit recombinant vaccines are also of interest but they
re still in preclinical development. At present, vaccine
ay not be available for the next 3-5 years because the
omplex immune reactions that are involved in dengue
mmunopathogenesis needs further clariﬁcation. In this
tudy, we propose a novel method of immortalizing and
loning Dengue virus speciﬁc B lymphocytes from conva-
escent patients secreting neutralizing antibodies. Upon
hich, DNA from these B lymphocytes were extracted and
equenced. Sequential cloning method was employed to
lone in the variable light (VL) chain and variable heavy
VH) chain fragments into the IgG1 framework vector. This
ecombinant vector was transfected into suspension human
mbryonic kidney (HEK) 293 cells for transient expression
f the dengue-neutralizing antibodies belonging to the vari-
us IgG subclasses. The antibodies isolated will prove useful
ools for studying the immunology of Dengue virus infections
nd as possible future therapeutic reagents to prevent virus
issemination in infected individuals.
Methods: Ebv immortalization. ELISA. PRNT. Immunoﬂu-
rescent Microscopy. Molecular Cloning. Antibody puriﬁca-
ion.
Results: Antibody generated.
Conclusion: Human antibody responses are important
o resolve Dengue infections naturally and the best strat-
gy is to isolate and produce the anti-dengue antibodies
hat resolve infections in human patients. These thera-
eutic antibodies are have predictable pharmacokinetics
roperties and display low toxicological risk. A research col-
aboration involving the National University of Singapore
NUS), Novartis Institute of Tropical Diseases, Singapore
NITD) and Defence Science National Laboratories, Singa-
ore (DSO) aims to produce human monoclonal antibodies
mAb), that can efﬁciently neutralize the Dengue virus. Each
ntibody will be fully cloned and expressed recombinantly
s IgG class.
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Background: In August 2007 the Government of Ontario
nnounced that, for the ﬁrst time, it was offering the
uadravalent HPV vaccine to grade 8 females in all Toronto
chools beginning September 2007. Uptake of the vaccine in
he 2007/2008 province-wide program was much lower than
nticipated. The provincial HPV vaccination rate was 58%
or the ﬁrst dose, which was lower than other school-based
accination programs. For a vaccine with such far-reaching
mpact on a woman’s health, this is a disappointing and not
ell understood outcome. We assessed parental factors for
nd against the HPV vaccine.
Methods: A random sample of parents of grade 8 females
n Toronto who were eligible for the publicly-funded HPV
accine in the 2007-2008 academic session were asked to
espond to questions regarding the HPV vaccine program
n Toronto. We conducted telephone interviews and used
tandardized questionnaires to capture data. We conducted
ivariate statistics to compare the responses of parents who
llowed their daughters to be vaccinated against HPV with
hose of parents who did not. Multivariate logistic regression
tatistics was calculated with SPSS to identify the predictive
actors that were signiﬁcantly associated with HPV vaccine
ptake.
Results: Of the 138 respondents, 75.4% had vaccinated
heir daughters. Concern over safety of the vaccine (27.3%)
nd inadequate information (21.2%) were the most com-
only reported reasons given by parents to not allow their
aughters to be vaccinated. Religious afﬁliation was not
ssociated with a difference in parental decision to vacci-
ate. Parents whose daughters were vaccinated were more
ikely to agree with the importance of vaccination prior to
exual activity onset (OR=10.46, 95% CI: 1.72-63.59, p<0.05)
han parents whose daughters were not vaccinated. Par-
nts whose daughters were vaccinated were less likely to
gree that vaccination would encourage earlier sexual activ-
ty (OR=0.14, 95% CI: 0.02-0.91, p<0.05) than parents who
id not approve vaccination for their daughters.
Conclusion: Parents need more information about safety
nd efﬁcacy of the vaccine. Parental attitudes towards the
mportance of vaccinating before becoming sexually active
